146 related articles for article (PubMed ID: 17562112)
1. Omental chemotherapy effects as a prognostic factor in ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
Le T; Williams K; Senterman M; Hopkins L; Faught W; Fung-Kee-Fung M
Ann Surg Oncol; 2007 Sep; 14(9):2649-53. PubMed ID: 17562112
[TBL] [Abstract][Full Text] [Related]
2. Histopathologic assessment of chemotherapy effects in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
Le T; Williams K; Senterman M; Hopkins L; Faught W; Fung-Kee-Fung M
Gynecol Oncol; 2007 Jul; 106(1):160-3. PubMed ID: 17490737
[TBL] [Abstract][Full Text] [Related]
3. The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
Le T; Hopkins L; Faught W; Fung-Kee-Fung M
Gynecol Oncol; 2007 Jun; 105(3):712-5. PubMed ID: 17400284
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
Le T; Alshaikh G; Hopkins L; Faught W; Fung MF
Ann Surg Oncol; 2006 Dec; 13(12):1711-6. PubMed ID: 17009146
[TBL] [Abstract][Full Text] [Related]
5. [Neo-adjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer treatment--a retrospective study].
Tkácová M; Vertaková-Krakovská B; Belohorská B; Miskovská V; Helpianska L; Ondrus D; Ondrusová M; Spánik S; Svec J
Klin Onkol; 2009; 22(6):273-7. PubMed ID: 20099745
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Wimberger P; Lehmann N; Kimmig R; Burges A; Meier W; Du Bois A;
Gynecol Oncol; 2007 Jul; 106(1):69-74. PubMed ID: 17397910
[TBL] [Abstract][Full Text] [Related]
7. Carcinosarcoma of the ovary-a case series.
Rutledge TL; Gold MA; McMeekin DS; Huh WK; Powell MA; Lewin SN; Mutch DG; Johnson GA; Walker JL; Mannel RS
Gynecol Oncol; 2006 Jan; 100(1):128-32. PubMed ID: 16213011
[TBL] [Abstract][Full Text] [Related]
8. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
[TBL] [Abstract][Full Text] [Related]
9. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
Pecorelli S; Favalli G; Gadducci A; Katsaros D; Panici PB; Carpi A; Scambia G; Ballardini M; Nanni O; Conte P;
J Clin Oncol; 2009 Oct; 27(28):4642-8. PubMed ID: 19704064
[TBL] [Abstract][Full Text] [Related]
10. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer.
Karam AK; Chiang JW; Fung E; Nossov V; Karlan BY
Gynecol Oncol; 2009 Aug; 114(2):246-52. PubMed ID: 19500821
[TBL] [Abstract][Full Text] [Related]
11. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
[TBL] [Abstract][Full Text] [Related]
12. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
[TBL] [Abstract][Full Text] [Related]
13. Is neo-adjuvant chemotherapy a "waiver" of extensive upper abdominal surgery in advanced epithelial ovarian cancer?
Kang S; Jong YH; Hwang JH; Lim MC; Seo SS; Yoo CW; Park SY
Ann Surg Oncol; 2011 Dec; 18(13):3824-7. PubMed ID: 21691879
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.
Hou JY; Kelly MG; Yu H; McAlpine JN; Azodi M; Rutherford TJ; Schwartz PE
Gynecol Oncol; 2007 Apr; 105(1):211-7. PubMed ID: 17239941
[TBL] [Abstract][Full Text] [Related]
15. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
Safra T; Menczer J; Bernstein RM; Shpigel S; Matcejevsky D; Inbar MJ; Golan A; Grisaru D; Levy T
Gynecol Oncol; 2009 Aug; 114(2):215-8. PubMed ID: 19446318
[TBL] [Abstract][Full Text] [Related]
16. Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study.
; Secord AA; Lee PS; Darcy KM; Havrilesky LJ; Grace LA; Marks JR; Berchuck A
Gynecol Oncol; 2006 Jun; 101(3):390-7. PubMed ID: 16551475
[TBL] [Abstract][Full Text] [Related]
17. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival.
Alberts DS; Marth C; Alvarez RD; Johnson G; Bidzinski M; Kardatzke DR; Bradford WZ; Loutit J; Kirn DH; Clouser MC; Markman M;
Gynecol Oncol; 2008 May; 109(2):174-81. PubMed ID: 18314182
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic factors of ovarian cancer].
Ochiai K
Gan To Kagaku Ryoho; 2006 Dec; 33(13):2014-9. PubMed ID: 17197745
[TBL] [Abstract][Full Text] [Related]
20. Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery.
Bae JH; Lee JM; Ryu KS; Lee YS; Park YG; Hur SY; Ahn WS; Namkoong SE
Gynecol Oncol; 2007 Jul; 106(1):193-200. PubMed ID: 17466362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
